European Bioanalysis Forum feedback on draft ICH M10 guideline on bioanalytical method validation during the Step 2b public consultation period / Philip Timmerman, Joanne Goodman, Michaela Golob, Tobias Haslberger, Magnus Knutsson, Robert Nelson, Tom Verhaeghe, Steve White
Once released, the ICH M10 Guideline on bioanalytical method validation will become one of the most important milestones in the history of regulated bioanalysis, closing a chapter on intense discussions among the industry and health authorities started in Crystal City in 2001. In this manuscript, the European Bioanalysis Forum community reports back on their feedback on the ICH M10 draft guideline gathered during the public consultation period. The comments given are intended to contribute to a guideline that combines several decades of experience and current scientific vision. They should provide future generations of bioanalytical scientist a regulatory framework so their bioanalytical work can contribute to safe, effective and high-quality medicines, which can be developed and registered in the most resource-efficient manner.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Bioanalysis - 12(2020), 6, Seite 1- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Timmerman, Philip [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (11 p) |
|---|
| doi: |
10.4155/bio-2020-0065 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL001042440 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001042440 | ||
| 003 | DE-627 | ||
| 005 | 20230430080653.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2020-0065 |2 doi | |
| 035 | |a (DE-627)KFL001042440 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/bio-2020-0065 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Timmerman, Philip |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a European Bioanalysis Forum feedback on draft ICH M10 guideline on bioanalytical method validation during the Step 2b public consultation period |c Philip Timmerman, Joanne Goodman, Michaela Golob, Tobias Haslberger, Magnus Knutsson, Robert Nelson, Tom Verhaeghe, Steve White |
| 264 | 1 | |c 2020 | |
| 300 | |a 1 Online-Ressource (11 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Once released, the ICH M10 Guideline on bioanalytical method validation will become one of the most important milestones in the history of regulated bioanalysis, closing a chapter on intense discussions among the industry and health authorities started in Crystal City in 2001. In this manuscript, the European Bioanalysis Forum community reports back on their feedback on the ICH M10 draft guideline gathered during the public consultation period. The comments given are intended to contribute to a guideline that combines several decades of experience and current scientific vision. They should provide future generations of bioanalytical scientist a regulatory framework so their bioanalytical work can contribute to safe, effective and high-quality medicines, which can be developed and registered in the most resource-efficient manner | ||
| 700 | 1 | |a Goodman, Joanne |e verfasserin |4 aut | |
| 700 | 1 | |a Golob, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Haslberger, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Knutsson, Magnus |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Verhaeghe, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a White, Steve |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d London : Future Science, 2009 |g 12(2020), 6, Seite 1- |h Online-Ressource |w (DE-627)KFL000038172 |w (DE-600)2571813-7 |w (DE-576)398101434 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:6 |g pages:1- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/bio-2020-0065 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 6 |h 1- | ||